<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37105192</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle><i>APOL1</i> and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>763</StartPage><EndPage>770</EndPage><MedlinePgn>763-770</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231172660</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) disproportionately affects individuals of African ancestry (AA) compared to European ancestry (EA). In the general population, high risk (HR) variants in the apolipoprotein L1 (<i>APOL1)</i> gene increase the risk of renal and hypertensive disorders in individuals of AA. Since SLE is characterized by an interferon signature and <i>APOL1</i> expression is driven by interferon, we examined the hypothesis that <i>APOL1</i> HR genotypes predominantly drive higher rates of renal and hypertensive-related comorbidities observed in SLE patients of AA versus those of EA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study in patients with SLE of EA and AA using a genetic biobank linked to de-identified electronic health records. <i>APOL1</i> HR genotypes were defined as G1/G1, G2/G2, or G1/G2 and low risk (LR) genotypes as 1 or 0 copies of the G1 and G2 alleles. To identify renal and hypertensive-related disorders that differed in prevalence by ancestry, we used a phenome-wide association approach. We then used logistic regression to compare the prevalence of renal and hypertensive-related disorders in EA and AA patients, both including and excluding patients with the <i>APOL1</i> HR genotype. In a sensitivity analysis, we examined the association of end stage renal disease secondary to lupus nephritis (LN-related ESRD) with ancestry and the <i>APOL1</i> genotype.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We studied 784 patients with SLE; 195 (24.9%) were of AA, of whom 27 (13.8%) had <i>APOL1</i> HR genotypes. Eighteen renal and hypertensive-related phenotypes were more common in AA than EA patients (<i>p-value</i> &#x2264; 1.4E-4). All phenotypes remained significantly different after exclusion of patients with <i>APOL1</i> HR genotypes, and most point odds ratios (ORs) decreased only slightly. Even among ORs with the greatest decrease, risk for AA patients without the <i>APOL1</i> HR genotype remained significantly elevated compared to EA patients. In the sensitivity analysis, LN-related ESRD was more prevalent in SLE patients of AA versus EA and AA patients with the <i>APOL1</i> HR genotype versus LR (<i>p-value</i> &lt; .05 for both).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The higher prevalence of renal and hypertensive disorders in SLE patients of AA compared to those of EA is not fully explained by the presence of <i>APOL1</i> high risk variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Cecilia P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Division of Rheumatology and Immunology, Department of Medicine Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System - Nashville Campus, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Miami VA Healthcare System, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakoc</LastName><ForeName>Gul</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Alyson</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3404-3802</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology and Immunology, Department of Medicine Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ge</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamboa</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosley</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Nancy J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Vivian K</ForeName><Initials>VK</Initials><Identifier Source="ORCID">0000-0001-5841-2575</Identifier><AffiliationInfo><Affiliation>Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation><Identifier Source="RINGGOLD">12328</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S10 RR025141</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024975</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR076516</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108666">APOL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075944">Apolipoprotein L1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075944" MajorTopicYN="Y">Apolipoprotein L1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APOL1</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">renal outcomes</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37105192</ArticleId><ArticleId IdType="mid">NIHMS1892218</ArticleId><ArticleId IdType="pmc">PMC10189827</ArticleId><ArticleId IdType="doi">10.1177/09612033231172660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chakravarty EF, Bush TM, Manzi S, et al.Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56: 2092&#x2013;2094. DOI: 10.1002/art.22641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22641</ArticleId><ArticleId IdType="pmc">PMC2530907</ArticleId><ArticleId IdType="pubmed">17530651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology (Oxford) 2017; 56: i67&#x2013;i77. DOI: 10.1093/rheumatology/kew399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew399</ArticleId><ArticleId IdType="pubmed">27940583</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Hiraki LT, Liu J, et al.Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013; 65: 753&#x2013;763. DOI: 10.1002/art.37795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37795</ArticleId><ArticleId IdType="pmc">PMC3733212</ArticleId><ArticleId IdType="pubmed">23203603</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers EC, Marder W, Cagnoli P, et al.Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol 2014; 66: 369&#x2013;378. DOI: 10.1002/art.38238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38238</ArticleId><ArticleId IdType="pmc">PMC4198147</ArticleId><ArticleId IdType="pubmed">24504809</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnado A, Carroll RJ, Casey C, et al.Phenome-wide association study identifies marked increased in burden of comorbidities in African Americans with systemic lupus erythematosus. Arthritis Res Ther 2018; 20: 69. DOI: 10.1186/s13075-018-1561-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1561-8</ArticleId><ArticleId IdType="pmc">PMC5894248</ArticleId><ArticleId IdType="pubmed">29636090</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman JS, Khan OA, Shuey MM, et al.Increased incidence of resistant hypertension in patients with systemic lupus erythematosus: a retrospective cohort study. Arthritis Care Res (Hoboken) 2020; 72: 534&#x2013;543. DOI: 10.1002/acr.23880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23880</ArticleId><ArticleId IdType="pmc">PMC6745299</ArticleId><ArticleId IdType="pubmed">30875459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostchega Y, Fryar CD, Nwankwo T, et al.Hypertension prevalence among adults aged 18 and over: United States, 2017-2018, NCHS Data Brief 1&#x2013;8, 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32487290</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen KL, Chertow GM, Foley RN, et al.US renal data system 2020 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2021; 77: A7&#x2013;A8. DOI: 10.1053/j.ajkd.2021.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.01.002</ArticleId><ArticleId IdType="pmc">PMC8148988</ArticleId><ArticleId IdType="pubmed">33752804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Zhang Y, Lin Z, et al.Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. Nat Commun 2021; 12: 772&#x2013;2021. DOI: 10.1038/s41467-021-21049-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21049-y</ArticleId><ArticleId IdType="pmc">PMC7858632</ArticleId><ArticleId IdType="pubmed">33536424</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando MM, Freudenberg J, Lee A, et al.Transancestral mapping of the MHC region in systemic lupus erythematosus identifies new independent and interacting loci at MSH5, HLA-DPB1 and HLA-G. Ann Rheum Dis 2012; 71: 777&#x2013;784. DOI: 10.1136/annrheumdis-2011-200808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200808</ArticleId><ArticleId IdType="pmc">PMC3329227</ArticleId><ArticleId IdType="pubmed">22233601</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen KA, Grammer AC, Lipsky PE. Deconvoluting the heterogeneity of SLE: the contribution of ancestry. J Allergy Clin Immunol 2022; 149: 12&#x2013;23. DOI: 10.1016/j.jaci.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.11.005</ArticleId><ArticleId IdType="pubmed">34857396</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman BI, Langefeld CD, Andringa KK, et al.End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014; 66: 390&#x2013;396. DOI: 10.1002/art.38220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38220</ArticleId><ArticleId IdType="pmc">PMC4002759</ArticleId><ArticleId IdType="pubmed">24504811</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf AA, Govender MA, Brandenburg JT, et al.Kidney disease and APOL1. Hum Mol Genet 2021; 30: R129&#x2013;R137. DOI: 10.1093/hmg/ddab024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab024</ArticleId><ArticleId IdType="pmc">PMC8117447</ArticleId><ArticleId IdType="pubmed">33744923</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol 2021; 16: 294&#x2013;303. DOI: 10.2215/cjn.15161219.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/cjn.15161219</ArticleId><ArticleId IdType="pmc">PMC7863644</ArticleId><ArticleId IdType="pubmed">32616495</ArticleId></ArticleIdList></Reference><Reference><Citation>Reidy KJ, Hjorten R, Parekh RS. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry. Curr Opin Pediatr 2018; 30: 252&#x2013;259. DOI: 10.1097/mop.0000000000000603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/mop.0000000000000603</ArticleId><ArticleId IdType="pmc">PMC6002812</ArticleId><ArticleId IdType="pubmed">29406442</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsa A, Kao WH, Xie D, et al.APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013; 369: 2183&#x2013;2196. DOI: 10.1056/NEJMoa1310345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1310345</ArticleId><ArticleId IdType="pmc">PMC3969022</ArticleId><ArticleId IdType="pubmed">24206458</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EE, Malik HS. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res 2009; 19: 850&#x2013;858. DOI: 10.1101/gr.085647.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.085647.108</ArticleId><ArticleId IdType="pmc">PMC2675973</ArticleId><ArticleId IdType="pubmed">19299565</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese G, Friedman DJ, Ross MD, et al.Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841&#x2013;845. DOI: 10.1126/science.1193032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1193032</ArticleId><ArticleId IdType="pmc">PMC2980843</ArticleId><ArticleId IdType="pubmed">20647424</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander TA, Machiela MJ. LDpop: an interactive online tool to calculate and visualize geographic LD patterns. BMC Bioinformatics 2020; 21: 14. DOI: 10.1186/s12859-020-3340-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-020-3340-1</ArticleId><ArticleId IdType="pmc">PMC6954550</ArticleId><ArticleId IdType="pubmed">31924160</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni GN, Galarneau G, Ellis SB, et al.Apolipoprotein L1 variants and blood pressure traits in african Americans. J Am Coll Cardiol 2017; 69: 1564&#x2013;1574. DOI: 10.1016/j.jacc.2017.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.01.040</ArticleId><ArticleId IdType="pmc">PMC5479565</ArticleId><ArticleId IdType="pubmed">28335839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols B, Jog P, Lee JH, et al.Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 2015; 87: 332&#x2013;342. DOI: 10.1038/ki.2014.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.270</ArticleId><ArticleId IdType="pmc">PMC4312530</ArticleId><ArticleId IdType="pubmed">25100047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019; 6: e000270. DOI: 10.1136/lupus-2018-000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000270</ArticleId><ArticleId IdType="pmc">PMC6703304</ArticleId><ArticleId IdType="pubmed">31497305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajgel G, Lima SC, Santana DJS, et al.Effect of a single apolipoprotein L1 gene nephropathy variant on the risk of advanced lupus nephritis in Brazilians. J Rheumatol 2020; 47: 1209&#x2013;1217. DOI: 10.3899/jrheum.190684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.190684</ArticleId><ArticleId IdType="pmc">PMC7225043</ArticleId><ArticleId IdType="pubmed">31732553</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazer A, Dey ID, Nwaukoni J, et al.Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study. Lupus Sci Med 2021; 8: e000460. DOI: 10.1136/lupus-2020-000460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000460</ArticleId><ArticleId IdType="pmc">PMC7816898</ArticleId><ArticleId IdType="pubmed">33461980</ArticleId></ArticleIdList></Reference><Reference><Citation>Daehn IS, Duffield JS. The glomerular filtration barrier: a structural target for novel kidney therapies. Nat Rev Drug Discov 2021; 20: 770&#x2013;788. DOI: 10.1038/s41573-021-00242-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00242-0</ArticleId><ArticleId IdType="pmc">PMC8278373</ArticleId><ArticleId IdType="pubmed">34262140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulley JM, Harris PA, Yarbrough T, et al.An informatics-based tool to assist researchers in initiating research at an academic medical center: vanderbilt customized action plan. Acad Med 2010; 85: 164&#x2013;168. DOI: 10.1097/ACM.0b013e3181c481bf.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACM.0b013e3181c481bf</ArticleId><ArticleId IdType="pmc">PMC3767144</ArticleId><ArticleId IdType="pubmed">20042844</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden DM, Pulley JM, Basford MA, et al.Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008; 84: 362&#x2013;369. DOI: 10.1038/clpt.2008.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2008.89</ArticleId><ArticleId IdType="pmc">PMC3763939</ArticleId><ArticleId IdType="pubmed">18500243</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnado A, Casey C, Carroll RJ, et al.Developing electronic health record algorithms that accurately identify patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017; 69: 687&#x2013;693. DOI: 10.1002/acr.22989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22989</ArticleId><ArticleId IdType="pmc">PMC5219863</ArticleId><ArticleId IdType="pubmed">27390187</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz GS, D&#x2019;Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007; 71: 491&#x2013;495. DOI: 10.1038/sj.ki.5002118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5002118</ArticleId><ArticleId IdType="pubmed">17264872</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishman E, Gerber MA, Churg J. Patterns of renal injury in systemic lupus erythematosus: light and immunofluorescence microscopic observations. Am J Kidney Dis 1982; 2: 135&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">6213149</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Gifford A, Meng X, et al.Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow development and initial evaluation. JMIR Med Inform 2019; 7: e14325. DOI: 10.2196/14325.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14325</ArticleId><ArticleId IdType="pmc">PMC6911227</ArticleId><ArticleId IdType="pubmed">31553307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei WQ, Bastarache LA, Carroll RJ, et al.Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS One 2017; 12: e0175508. DOI: 10.1371/journal.pone.0175508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0175508</ArticleId><ArticleId IdType="pmc">PMC5501393</ArticleId><ArticleId IdType="pubmed">28686612</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CC, Chow CC, Tellier LC, et al.Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7. DOI: 10.1186/s13742-015-0047-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13742-015-0047-8</ArticleId><ArticleId IdType="pmc">PMC4342193</ArticleId><ArticleId IdType="pubmed">25722852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Levine D, Shen J, et al.A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinformatics 2012; 28: 3326&#x2013;3328. DOI: 10.1093/bioinformatics/bts606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts606</ArticleId><ArticleId IdType="pmc">PMC3519454</ArticleId><ArticleId IdType="pubmed">23060615</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler DM, Gibbs RA, Peltonen L, et al.Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52&#x2013;58. DOI: 10.1038/nature09298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09298</ArticleId><ArticleId IdType="pmc">PMC3173859</ArticleId><ArticleId IdType="pubmed">20811451</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Forer L, Schonherr S, et al.Next-generation genotype imputation service and methods. Nat Genet 2016; 48: 1284&#x2013;1287. DOI: 10.1038/ng.3656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3656</ArticleId><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Littman AJ, Boyko EJ, McDonell MB, et al.Evaluation of a weight management program for veterans. Prev Chronic Dis 2012; 9: E99. DOI: 10.5888/pcd9.110267.</Citation><ArticleIdList><ArticleId IdType="doi">10.5888/pcd9.110267</ArticleId><ArticleId IdType="pmc">PMC3437789</ArticleId><ArticleId IdType="pubmed">22595323</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Bastarache L, Denny JCRPWAS. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics 2014; 30: 2375&#x2013;2376. DOI: 10.1093/bioinformatics/btu197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu197</ArticleId><ArticleId IdType="pmc">PMC4133579</ArticleId><ArticleId IdType="pubmed">24733291</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman DJ, Kozlitina J, Genovese G, et al.Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22: 2098&#x2013;2105. DOI: 10.1681/asn.2011050519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.2011050519</ArticleId><ArticleId IdType="pmc">PMC3231785</ArticleId><ArticleId IdType="pubmed">21997396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SS, Bayakly AR, Helmick CG, et al.The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry. Arthritis Rheumatol 2014; 66: 357&#x2013;368. DOI: 10.1002/art.38239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38239</ArticleId><ArticleId IdType="pmc">PMC4617771</ArticleId><ArticleId IdType="pubmed">24504808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez LA, Toloza SM, McGwin G, Jr., et al.Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus 2013; 22: 1214&#x2013;1224. DOI: 10.1177/0961203313502571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313502571</ArticleId><ArticleId IdType="pubmed">24097993</ArticleId></ArticleIdList></Reference><Reference><Citation>Maningding E, Dall'Era M, Trupin L, et al.Racial and ethnic differences in the prevalence and time to onset of manifestations of systemic lupus erythematosus: the California lupus surveillance project. Arthritis Care Res (Hoboken) 2020; 72: 622&#x2013;629. DOI: 10.1002/acr.23887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23887</ArticleId><ArticleId IdType="pmc">PMC6872905</ArticleId><ArticleId IdType="pubmed">31115180</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Gonzalez LA, Roseman JM, et al.Predictors of the rate of change in disease activity over time in LUMINA, a multiethnic US cohort of patients with systemic lupus erythematosus: LUMINA LXX. Lupus 2010; 19: 727&#x2013;733. DOI: 10.1177/0961203309359289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309359289</ArticleId><ArticleId IdType="pmc">PMC3964002</ArticleId><ArticleId IdType="pubmed">20118158</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ, et al.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222&#x2013;233. DOI: 10.1002/art.27233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Hogan S, Jennette C, et al.Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188&#x2013;1195. DOI: 10.1038/ki.1997.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1997.162</ArticleId><ArticleId IdType="pubmed">9083285</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen CP, Beggs ML, Saeed M, et al.Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013; 24: 722&#x2013;725. DOI: 10.1681/ASN.2012121180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2012121180</ArticleId><ArticleId IdType="pmc">PMC3636799</ArticleId><ArticleId IdType="pubmed">23520206</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman BI, Langefeld CD, Turner J, et al.Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 2012; 82: 805&#x2013;811. DOI: 10.1038/ki.2012.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.217</ArticleId><ArticleId IdType="pmc">PMC3443536</ArticleId><ArticleId IdType="pubmed">22695330</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer HS, Gomez SL, Cheng I, et al.Relative impact of genetic ancestry and neighborhood socioeconomic status on all-cause mortality in self-identified African Americans. PLoS One 2022; 17: e0273735. DOI: 10.1371/journal.pone.0273735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0273735</ArticleId><ArticleId IdType="pmc">PMC9423617</ArticleId><ArticleId IdType="pubmed">36037186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarcon GS, Bastian HM, Beasley TM, et al.Systemic lupus erythematosus in a multi-ethnic cohort (LUMINA) XXXII: [corrected] contributions of admixture and socioeconomic status to renal involvement. Lupus 2006; 15: 26&#x2013;31. DOI: 10.1191/0961203306lu2260oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203306lu2260oa</ArticleId><ArticleId IdType="pubmed">16482742</ArticleId></ArticleIdList></Reference><Reference><Citation>Richman IB, Taylor KE, Chung SA, et al.European genetic ancestry is associated with a decreased risk of lupus nephritis. Arthritis Rheum 2012; 64: 3374&#x2013;3382. DOI: 10.1002/art.34567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34567</ArticleId><ArticleId IdType="pmc">PMC3865923</ArticleId><ArticleId IdType="pubmed">23023776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>